RALP1 Rhoptry Neck Erythrocyte-Binding Protein Plasmodium
falciparum Merozoites Potential Blood-Stage Vaccine Candidate
Antigen
Daisuke Ito Tomoyuki Hasegawa Kazutoyo Miura,b Tsutomu Yamasaki  Thangavelu U. Arumugam Amporn Thongkukiatkul,c
Satoru Takeo  Eizo Takashima Jetsumon Sattabongkot,d Eun-Taek Han,e Carole  Long,b Motomi Torii,f Takafumi Tsuboia,g
Division Malaria Research, Proteo-Science Center Venture Business Laboratory,g Ehime University, Matsuyama, Ehime, Japan; Laboratory Malaria Vector
Research, National Institute Allergy Infectious Diseases, National Institutes Health, Rockville, Maryland, USAb; Department Biology, Faculty Science, Burapha
University, Chonburi, Thailandc; Mahidol Vivax Research Unit, Faculty Tropical Medicine, Mahidol University, Bangkok, Thailandd; Department Medical Environmental
Biology Tropical Medicine, School Medicine, Kangwon National University, Chuncheon, Gangwon  Republic Koreae; Division Molecular Parasitology,
Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime, Japanf

Erythrocyte invasion merozoites obligatory stage Plasmodium infection essential disease progression. Pro-
teins apical organelles merozoites mediate invasion erythrocytes potential malaria vaccine candidates.
Rhoptry-associated, leucine zipper-like protein 1 (RALP1) Plasmodium falciparum previously specifically
expressed schizont stages localized rhoptries merozoites immunofluorescence assay (IFA).  RALP1 refractory gene knockout attempts, suggesting essential blood-stage parasite survival. characteristics
suggest RALP1 potential blood-stage vaccine candidate antigen, assessed potential regard.
Antibodies raised recombinant RALP1 proteins synthesized using wheat germ cell-free  Immunoelec-
tron microscopy demonstrated time RALP1 rhoptry neck protein merozoites.  IFA data
showed RALP1 translocates rhoptry neck moving junction merozoite invasion. Growth invasion
inhibition assays revealed anti-RALP1 antibodies inhibit invasion erythrocytes merozoites. findings RALP1 possesses erythrocyte-binding epitope C-terminal region anti-RALP1 antibodies disrupt tight-junction
formation, evidence RALP1 plays important role merozoite invasion erythrocytes. addition, human sera
collected areas Thailand Mali malaria endemic recognized protein. Overall, findings indicate RALP1 rhoptry neck erythrocyte-binding protein qualifies potential blood-stage vaccine candidate.




P   lasmodium falciparum virulent malaria parasite     species infecting humans, affecting 216 million
individuals killing 0.7 million individuals 2010
                                                                                        parasitophorous vacuole (PV). attachment merozoites                                                                                         erythrocytes, rhoptry proteins mediate direct high-affinity mero-
                                                                                        zoite-erythrocyte interactions micronemal proteins (7) worldwide (1). half 1950s, appearance                    ultimately lead tight-junction formation irreversible com-
malaria parasites resistance antimalarial drugs mos-                     mitment merozoite invasion. tight junction char-
quito vectors resistance insecticides highlighted                       acterized electron-dense thickening erythrocyte
importance malaria vaccine development. number                            membrane merozoite, molecular makeup vaccine candidates developed tested preclini-                       fully understood, known include number cal clinical trials, limited clinical success                         rhoptry neck proteins (RONs), micronemal protein
achieved vaccines date (2, 3).  discovery novel                    AMA1 (8, 9). hand, proteins belonging vaccine candidates currently important step                        reticulocyte-binding-like homologue (Rh) protein family, located
renewed focus control, local elimination, eventual global                        rhoptries, shown translocate bind eryth-
eradication efforts (4).
    symptoms malaria caused blood-stage cyclic 
fection subsequent rupture hostâ€™s erythrocytes obli-                          Received 1 June 2013 Returned modification 10 July 2013
                                                                                            Accepted 29 August 2013
gate asexual intracellular malaria parasites. Erythrocyte invasion
                                                                                            Published ahead print 3 September 2013 merozoite, invasive form blood-stage parasite
                                                                                            Editor: J. H. Adams
exposed human immunity, mediated complex set                                                                                             Address correspondence Takafumi Tsuboi, tsuboi@ccr.ehime-u.ac.jp.
interactions different parasite ligands erythrocyte 
                                                                                            * Present address: Tsutomu Yamasaki, Department Life Science, Faculty ceptors (5â€“7). ligands used merozoite invasion
                                                                                            Science, Okayama University Science, Okayama, Japan; Satoru Takeo, Division expressed surface merozoite discharged                          Tropical Diseases Parasitology, Department Infectious Diseases, Faculty specialized apical organelles (rhoptries, micronemes,                              Medicine, Kyorin University, Mitaka, Tokyo, Japan.
dense granules) (5â€“7). apical organelles, rhoptries                           Supplemental material article http://dx.doi.org/10.1128 prominent large secretory organelles present pairs                           /IAI.00690-13. apical tip merozoite contents thought                        Copyright Â© 2013, American Society Microbiology. Rights Reserved.
important invasion processes, initial host                           doi:10.1128/IAI.00690-13
cell sensing, tight-junction formation, establishment 

4290   iai.asm.org                                    Infection Immunity    p. 4290 â€“ 4298                                      November 2013 Volume 81 Number 11
                                                                                                    P. falciparum RALP1, Potential Malaria Vaccine Candidate



rocytes, leading tight-junction formation, play di-             region RALP1, encompassing 396 aa [F17 Q412]), RALP1-C1 (C-
rect role invasion (10). way, rhoptry proteins                terminal region RALP1, encompassing 239 aa [N396 P634]), represent promising blood-stage P. falciparum vaccine candidates.              RALP1-C2 (C-terminal region RALP1, encompassing 315 aa [N396  study taken objective character-            K710]) amplified P. falciparum 3D7 genomic DNA PCR izing P. falciparum rhoptry proteins assessing novel               using sense primers XhoI sites antisense primers BamHI
blood-stage vaccine candidates.                                                restriction sites  lowercase letters primer sequences .
    Previous bioinformatic searches using transcriptional                  Primers RALP1-N1-F (5=-ctcgagATGCCACTTCAACGTGGCGCATC-
                                                                               3=) RALP1-N1-R (5=-ggatccCTAGTGATGATGATGATGATGATCA
structural features known proteins Haase et al. (11)                                                                                ACGTTCACATTCATTTGTTGATT-3=), primers RALP1-N2-F (5=-ctcga
identified hypothetical proteins probably located                                                                                gTTTTACCTGATAAAGTCATCTTCCAAT-3=) RALP1-N2-R (5=-g surface merozoite secretory organelles.                gatccCTATTGATCATTCATCAATTTTACAAAAAC-3=), primers candidates, experimentally shown                        RALP1-C1-F (5=-ctcgagAATGGTAAGAAGGATAAAAATGGGGT-3=)
PF3D7_0722200 appears localized rhoptry P.                     RALP1-C1-R (5=-ggatccCTATGGTACATTTTTAGGTGTAAAAGT
falciparum merozoites possess leucine zipper-like                  AGT-3=), primers RALP1-C2-F (5=-ctcgagAATGGTAAGAAGGATA
main, structural feature facilitates protein-protein inter-             AAAATGGGGT-3=) RALP1-C2-R (5=-ggatccCTATTTGTTTCCCA
action, designated rhoptry-associated leucine zip-                TATCATTTTTATTATATTT-3=) used generate DNA like protein 1 (RALP1). Furthermore, RALP1 conserved                 fragments encoding RALP1-N1, -N2, -C1, -C2 proteins, respec-
Plasmodium spp. refractory gene knockout attempts (11),           tively. underlined sequences primer RALP1-N1-R indicate 
suggesting RALP1 play important role invasion.                gions encode hexahistidine tag.  far, studies attempted growth invasion                  amplified fragments restricted ligated inhibition assays antibodies raised recombinant RALP1             wheat germ cell-free expression vectors (CellFree Sciences). fragment
proteins;  RALP1 characterized vaccine            encoding RALP1-N1 cloned pEU-E01-MCS vector. Frag-
candidate. study, attempted test RALP1              ments encoding RALP1-N2, -C1, -C2 cloned pEU-E01-
                                                                               GST-TEV-N2 vector. cloned inserts sequenced ABI
potential blood-stage vaccine candidate. regard, expressed
                                                                               PRISM 3100-Avant genetic analyzer (Applied Biosystems, Foster City,
recombinant RALP1 using wheat germ cell-free                  CA). recombinant proteins glutathione S-trans-
fined subcellular localization RALP1 immunoelectron mi-              ferase (GST) tag expressed wheat germ cell-free croscopy (IEM), tested growth invasion inhibition activity          purified nickel-Sepharose column (GE Healthcare) anti-RALP1 antibodies, analyzed reactivity malaria im-           case RALP1-C1 glutathione-Sepharose 4B column (GE Health-
mune human sera RALP1.                                                      care). GST-tagged RALP1-N2 purified glutathione elution.                                                                                case GST-tagged RALP1-C1 -C2 proteins, N-terminal GST
MATERIALS METHODS                                                          tag removed eluting GST-tagged RALP1 bound glutathione-
Parasite culture free-merozoite purification. P. falciparum asexual        Sepharose 4B column using tobacco etch virus (TEV) protease, stages (strain 3D7A National Institute Allergy Infectious      cleaves TEV recognition site GST tag RALP1
Diseases [NIAID], NIH) maintained vitro erythrocytes           fragment. detailed methods used wheat germ cell-free pro-
healthy human donors (blood group Oâ«¹) obtained Japanese Red           tein synthesis affinity purification described previously (16).
Cross Society described (12). harvest parasite pellets, ma-        generate antisera protein (RALP1-N1, -C1, -C2),
ture schizonts purified differential centrifugation 70 /40        BALB/c mice immunized subcutaneously 20 â?®g purified
Percoll-sorbitol gradient treated tetanolysin (List Biolog-   recombinant protein emulsified Freundâ€™s complete adjuvant, fol-
ical Laboratories, , Campbell, CA) remove hemoglobin loss       lowed 20 â?®g protein Freundâ€™s incomplete adjuvant. parasite proteins present PV space (13), washed phosphate-      Japanese white rabbit immunized subcutaneously 250 â?®g buffered saline (PBS) containing Complete protease inhibitor (Roche,           purified protein Freundâ€™s complete adjuvant, followed 250 â?®g Mannheim, Germany), stored â«º80Â°C used. viable free            purified protein Freundâ€™s incomplete adjuvant. immunizations
merozoites retain invasive capacity purified basis   times 3-week intervals, antisera collected recently reported protocol (14). Briefly, parasites synchronized
                                                                               14 days immunization. animal experimental pro- using sorbitol treatment heparin (Mochida Pharmaceutical ,
                                                                               tocols approved Institutional Animal Care Use Commit-
Tokyo, Japan). Late-stage parasites (32 36 h postinvasion) purified
                                                                               tee Ehime University (su-14-6), experiments conducted
(â¬Ž95  purity) magnetic separation MACS CS column 
                                                                               according Ethical Guidelines Animal Experiments Ehime
junction VarioMACS magnetic separator (Miltenyi Biotec, Cam-
                                                                               University. similar manner, mouse anti-RAP1 (M1 D782 3D7
bridge, MA), incubated 10 â?®M E64 (Sigma-Aldrich Corporation, St.
Louis, MO) 6 8 h, pelleted. Resulting E64-treated schizonts    sequence [PF3D7_1410400]) antibody, mouse rabbit anti-AMA1
resuspended small volume incomplete culture medium (contain-           (Q25 K546 3D7 sequence [PF3D7_1133400]) antibodies, ing protein component) filtered 1.2-â?®m Acrodisc               rabbit anti-GST antibody generated previously described (17).
32-mm syringe filter (Pall Corporation, Port Washington, NY).                  Mouse anti-RON4 monoclonal antibody (26C64F12) (8) kind gift
    Production recombinant proteins antisera. Genomic DNA               Jean F. Dubremetz (UniversitÃ© Montpellier 2, Montpellier, extracted P. falciparum strain 3D7A DNAzol reagent           France).
(Invitrogen, Carlsbad, CA). nucleotide sequence ralp1 gene              order obtain antigen-specific IgGs, rabbit antisera RALP1
(PF3D7_0722200) strain 3D7 obtained malaria genome             proteins affinity purified columns conjugated respective
database PlasmoDB (http://plasmodb.org). order generate specific         recombinant RALP1 proteins ligands. Briefly, recombinant RALP1
antibodies, truncated regions ralp1 gene amplified ex-         proteins covalently linked HiTrap NHS-Activated HP columns
pressed recombinant proteins wheat germ cell-free translation      (GE Healthcare) accordance manufacturerâ€™s recommenda- (CellFree Sciences, Matsuyama, Japan) described previously           tions. Rabbit antisera applied RALP1 protein-conjugated
(15). Briefly, PF3D7_0722200 fragments encoding RALP1-N1 (N-               column. extensive washing 20 mM phosphate buffer (pH 7.0),
terminal region RALP1, encompassing 114 amino acids [aa; M35             antigen-specific IgGs eluted 0.1 M glycine-HCl, pH 2.5, D148] hexahistidine tag C terminus), RALP1-N2 (N-terminal         immediately neutralized 1 M Tris, pH 9.0.


November 2013 Volume 81 Number 11                                                                                                           iai.asm.org 4291
Ito et al.



     Preparation parasite schizont extract Western blot analysis.       flow cytometry described previously (19). Briefly, parasite cultures
Purified, schizont-rich parasite pellets lysed appropriate          synchronized day start GIA, majority reducing SDS-PAGE sample buffer incubated 98Â°C           parasites late trophozoite schizont stage start 3 min. lysate centrifuged 10,000 â«» g 10 min room         GIA. microliters parasite-infected erythrocyte (pRBC) suspen-
temperature (RT), supernatants subjected electrophoresis        sion (0.3  parasitemia 2  hematocrit) 20 â?®l IgGs added 12.5  polyacrylamide gel (ATTO, Tokyo, Japan). Proteins            half-area flat 96 cell culture microplates (Corn-
transferred 0.2-â?®m polyvinylidene difluoride membrane (Hybond             ing, Corning, NY) gently mixed. control, 20 â?®l culture 
LFP; GE Healthcare) semidry blotting (ATTO). mem-            dium added pRBC suspension. Cultures incubated 37Â°C
branes blocked PBS-MT (PBS containing 5  [wt/vol] nonfat             humidified, gassed (90  N2, 5  O2, 5  CO2), airtight boxes. milk 0.1  [vol/vol] Tween 20), lanes cut strips.        25 h incubation, invading parasites developed membrane strip immunostained antiserum RT 1          early trophozoite stage, pRBC pelleted brief centrifugation
h, followed horseradish peroxidase-conjugated secondary-antibody            (1,300 â«» g 5 min) washed 100 â?®l PBS. cells (GE Healthcare) probing, visualized Immobilon Western                 incubated 50 â?®l diluted (1:1,000 PBS) SYBR green (Invitro-
chemiluminescent horseradish peroxidase substrate (Millipore, Billerica,       gen) 10 min RT washed PBS. Parasitemia measured
MA) LAS 4000 Mini luminescent-image analyzer (GE Healthcare).             flow cytometry FACSCanto II (BD Biosciences, San Jose, CA) relative molecular masses proteins estimated refer-       acquisition 50,000 events sample. Data analyzed ence Precision Plus protein standards (Bio-Rad, Hercules, CA).              FlowJo 9.1 software (Tree Star, Ashley,  gating intact eryth-
     Imaging schizont merozoite invasion indirect immuno-            rocytes scatter forward scatter parameters subsequently
fluorescence assay (IFA). smears schizont-enriched P. falcipa-         determining proportion SYBR green positive cells. Samples rum-infected erythrocytes prepared glass slides stored          tested triplicate experiment, independent experi-
â«º80Â°C. smears thawed, fixed 4  paraformaldehyde RT            ments performed. 10 min, permeabilized PBS-T (PBS containing 0.1  Triton                   human IgGs purified serum samples Mali X-100) RT 15 min, blocked PBS containing 5  nonfat milk        tested parasite invasion growth-inhibitory activity cycle
(blocking solution) 37Â°C 30 min.                                        parasite replication GIA Reference Center, NIAID, NIH. GIA
     Free merozoites isolated described  added uninfected     reaction mixture incubated 40 h presence test IgG allow
erythrocytes, processed invasion described previously (14).         invading parasites develop schizont stage, Invading merozoites collected 2 10 min incubation        parasite growth determined biochemical assay specific para-
erythrocytes shaker 37Â°C, fixed RT 30 min 4  parafor-      site lactate dehydrogenase previously described (20).
maldehydeâ€“ 0.0075  glutaraldehyde PBS, permeabilized PBS-T              Immunoprecipitation. Immunoprecipitation carried pre-
RT 15 min, blocked PBS containing 3  bovine serum albumin             viously described (17). Briefly, proteins extracted late schizont
(BSA) 37Â°C 30 min, applied polyethyleneimine-coated         parasite pellets PBS 1  Triton X-100 containing Complete pro-
coverslips.                                                                    tease inhibitor. Fifty-microliter samples supernatants preincu-
     antigen samples IFA described stained pri-        bated 4Â°C 1 h 40 â?®l 50  protein G-conjugated beads (pro-
mary antibodies diluted following concentrations blocking solu-      tein G-Sepharose 4 Fast Flow; GE Healthcare) NETT buffer (50 mM
tion 37Â°C 1 h: rabbit anti-RALP1-C1 antibody, 1:500; rabbit anti-       Tris-HCl, 0.15 M NaCl, 1 mM EDTA, 0.5  Triton X-100) supplemented
RALP1-C2 antibody, 1:500; mouse anti-RALP1-N1 antibody, 1:100;                 0.5  BSA (fraction V; Sigma-Aldrich Corporation). Aliquots 
mouse anti-RAP1 antibody, 1:100 (17); mouse anti-RON4 monoclonal               covered supernatants incubated rabbit anti-RALP1-N1, anti-
antibody, 1:1,000 (gift Jean F. Dubremetz). Secondary antibodies,         RALP1-C1, anti-AMA1, anti-GST antibody, 40 â?®l 50 
Alexa Fluor 488-conjugated goat anti-rabbit IgG Alexa Fluor 568-           protein G-conjugated bead suspension added. incubation 1
conjugated goat anti-mouse IgG (Invitrogen), used 1:500 dilu-        h 4Â°C, beads washed NETTâ€“ 0.5  BSA, tion blocking solution 37Â°C 30 min. DAPI (4=,6-diamidino-2-          NETT, high-salt (0.5 M NaCl) NETT, NETT, phenylindole) 2 â?®g/ml added secondary-antibody              low-salt (0.05 M NaCl, 0.17  Triton X-100) NETT. Finally,
solution stain nuclei. Slides mounted ProLong Gold Anti-        proteins extracted protein G-conjugated beads incuba-
fade reagent (Invitrogen) viewed 63â«» oil immersion lens.           tion 1â«» SDS-PAGE reducing loading buffer 98Â°C 3 min. High-resolution image capture processing performed             supernatants used Western blot analysis.
confocal scanning laser microscope (LSM710; Carl Zeiss MicroImaging,               FACS-based EBA. assay checking erythrocyte-binding ac-
Thornwood, NY). Images processed Adobe Photoshop (Adobe                tivity RALP1 basis protocol used assay Systems , San Jose, CA).                                                   erythrocyte-binding activity Duffy antigen (21). Rh5 P. falciparum      IEM. Parasites fixed embedded LR White resin (Poly-           unique erythrocyte-binding proteins 
sciences, , Warrington, PA) previously described (18). Ultrathin        leted P. falciparum strain. native recombinant Rh5
sections immunostained previously described (19). Samples         previously shown bind erythrocytes (22).  used
examined transmission electron microscope (JEM-1230; JEOL,              Rh5 universal positive-control protein erythrocyte-binding 
Tokyo, Japan).                                                                 say (EBA). brief, GST-tagged RALP1-N2, RALP1-C1, length Rh5
     GIAs. Total rabbit IgGs growth inhibition assays (GIAs) pu-      (comprising aa E26 Q526 3D7 sequence [PF3D7_0424100] 
rified rabbit antisera HiTrap protein G-Sepharose columns (GE        signal peptide), GST (negative control) synthesized Healthcare) according manufacturerâ€™s protocol. Purified IgGs       wheat germ cell-free purified glutathione-Sepharose buffer exchanged incomplete culture medium, concentrated          column chromatography glutathione elution described  Amicon Ultra-15 centrifugal filter units (Millipore), filter sterilized   Erythrocytes washed times PBSâ€“1  BSA, resuspended Ultrafree-MC GV 0.22-â?®m centrifugal filter (Millipore), pre-       1 â«» 105 cells 200 â?®l PBSâ€“1  BSA, preincubated 20 â?®g
absorbed remove nonspecific antierythrocyte antibodies 25 â?®l        recombinant protein RT 3 h. preincubation, erythrocytes packed human Oâ«¹ erythrocytes purified IgG 1 ml antiserum           washed PBS incubated fluorescein isothiocyanate RT 1 h rotating wheel. Finally, concentrations rabbit   (FITC)-conjugated anti-GST antibody (1:100 PBS 1  BSA; Ab-
IgG samples adjusted 40 mg/ml incomplete culture medium.            cam, Cambridge, United Kingdom) RT 1 h protected      inhibitory activity rabbit IgGs merozoite invasion tested   light. Erythrocytes washed PBS  resuspended 200 â?®l cycle parasite replication, parasitemia determined      PBS, transferred fluorescence-activated cell sorter (FACS) tubes. 

4292     iai.asm.org                                                                                                                   Infection Immunity
                                                                                                 P. falciparum RALP1, Potential Malaria Vaccine Candidate



total 50,000 erythrocytes read FACSCanto II flow cytometer,      teins. N1, C1, C2 truncated proteins used immu- resulting flow cytometry data analyzed FlowJo software.     nize rabbits mice produce antibodies. percentage erythrocytes bound recombinant RALP1 (                  RALP1 expression analyzed RALP1-specific antibod-
cells) obtained percentage erythrocytes positive       ies Western blot assay protein extracts synchronized
FITC signal background FITC measurement erythrocytes             schizont-rich parasites. antisera raised N1, recombinant protein.
                                                                              C1, C2 truncated forms RALP1 recognized protein     IFA-based MIBA. Total IgGs tested merozoite invasion-
blocking assay (MIBA) purified rabbit antisera described         â¬Ž90 kDa protein extracts P. falciparum parasites schi-  filtered merozoites, antibodies added final       zont stages (Fig. 1C, arrowhead), corresponding predicted
centration 20 mg/ml total IgG anti-RALP1-C1 anti-GST serum        molecular mass 88 kDa. Additionally, anti-RALP1-N1 (diluted incomplete culture medium) uninfected erythrocytes            anti-RALP1-C1 anti-RALP1-C2 antisera recognized distinct
(50  hematocrit; 10 â?®l) incubated 37Â°C 10 min. Control assays      53- 50-kDa proteins, respectively, represent processed N- performed incomplete culture medium. fixation             C-terminal forms RALP1 protein (Fig. 1C, asterisks). washing, samples processed IFA DAPI mouse anti-             case anti-RALP1-C1 -C2 antiserum staining, faint
RAP1 antibody described  condition, biological        band 40 kDa visible, suggesting processing
replicates approximately 2,000 erythrocytes attached invading      event C-terminal region RALP1. negative-control
parasites scored confocal scanning laser microscope.
                                                                              lane stained secondary antibody showed signal
    ELISAs. Human serum samples western Thailand collected asymptomatic P. falciparum carriers written informed consent        (Fig. 1C, Ctrl), indicating signals described previously described (23). study approved Ethics Com-       specific.
mittee Thai Ministry Public Health Institutional Review         order confirm exact localization RALP1 mero-
Board Walter Reed Army Institute Research (WRAIR number             zoite rhoptries, used antisera RAP1, rhoptry bulb
802) (23). Human serum samples collected adults living      marker, RON4, rhoptry neck marker, test RALP1 resides village Kenieroba, Mali (24). study approved ethical    compartments IFA (Fig. 1D). IFA results showed
review committees Faculty Medicine, Pharmacy, Dentistry      apical distribution RALP1, detected anti-RALP1-C2 University Bamako (Mali) NIAID, National Institutes         antiserum, clearly RON4 (Fig. 1D, middle) Health, Bethesda, MD (NIAID protocol number 08 N120). Individual            RAP1 (Fig. 1D, . Furthermore, distribution written informed consent obtained participants. Measure-
                                                                              RALP1 detected anti-RALP1-C2 antiserum overlaps ments antibodies recombinant RALP1-C1 1:1,000-di-
luted Thai Mali sera performed previously described (24).      RALP1 detected anti-RALP1-N1 antiserum (Fig. 1D, .
enzyme-linked immunosorbent assays (ELISAs) replicated twice          IFA anti-RALP1-C1 antiserum shows RALP1 colocal-
dependently.                                                                  izes RON4  Fig. S1 supplemental material).
    Statistical analysis. Mann-Whitney U test used test            validate precise subcellular localization significance differences ELISA values groups, Spear-        RALP1 merozoite electron microscopy, parasites late
manâ€™s rank correlation test used test correlation ELISA    schizont stages stained RALP1-C2 specific IgG sub- GIA values. GIA EBA data, Kruskal-Wallis test used,       sequently secondary antibody labeled gold particles.
followed Dunnâ€™s multiple-comparison test examine differences        Gold particle signals detected neck portion negative-control- experimental-group values. MIBA,            rhoptries merozoites (Fig. 1E).  findings estab-
Fisherâ€™s exact test Bonferroni correction performed. statisti-
                                                                              lish RALP1 novel RON merozoites.
cal analyses performed GraphPad Prism (GraphPad Software,
San Diego, CA).                                                                   RALP1 translocates moving junction merozo-
                                                                              ite invasion. data study (11) supporting direct
RESULTS                                                                       role RALP1 parasite invasion limited. clear RALP1 localized merozoite rhoptry neck. order                 data RALP1 expressed rhoptry neck merozoite
characterize RALP1, produced recombinant RALP1 proteins                    antibodies inhibit merozoite invasion. Recent stud-
(Fig. 1A codon optimization. Figure 1B shows differ-              ies shown RONs Rhs tight-
ent truncated RALP1 proteins, RALP1-N1 (predicted molecular                   junction proteins, suggesting specific role RONs mass, 13.9 kDa), RALP1-C1 (27.5 kDa), RALP1-N2 (fused                    invasion process (10, 25). investigate role GST, 76.0 kDa), RALP1-C2 (37.4 kDa), resolved 12.5                   RALP1 merozoite invasion erythrocytes, performed
SDS-polyacrylamide gel stained Coomassie brilliant blue              IFA analyzed localization RALP1 reference R-250. N1, C1, C2 truncated versions RALP1 protein                 rhoptry neck bulb markers (RON4 RAP1), recovered supernatant fraction easily purified             shown previously localize tight junction PV,
single dominant bands (Fig. 1B, arrowheads) affinity chroma-               respectively, merozoite invasion (26). using invading
tography. electrophoretic mobility N1, C1, C2            merozoites, showed confocal microscopic examination proteins (Fig. 1B, arrowhead) slower, observed molecular             RALP1 colocalized RON4 moving junction 
masses higher predicted molecular masses.                 invasion process (Fig. 2A). Figure 2B shows RAP1 RALP1-N2 derived multiple bands, length                  fluorescence seen surrounding parasite PV late
band slightly faster electrophoretic mobility clearly seen           invasion stages.  RALP1 fluorescence observed (Fig. 1B, arrowhead). appearance smaller bands N2 pro-              PV posterior end parasite (Fig. 2B).
teins (Fig. 1B, asterisks) caused translational arrest          Taken  observations indicate RALP1 tight- reaction, smaller bands retain            junction protein suggest RALP1 play important
GST tag N terminus (data shown). results dem-                role merozoite invasion erythrocytes.
onstrate wheat germ cell-free able translate            RALP1 does interact AMA1. investigate native RALP1-encoding gene sequences produce soluble pro-                 RALP1 interacts known RON-AMA1 moving-junc-


November 2013 Volume 81 Number 11                                                                                                        iai.asm.org 4293
Ito et al.




                                                                                   FIG 2 RALP1 localized moving junction invasion. RALP1
                                                                                   colocalizes moving-junction marker (RON4) early                                                                                    mid late stages invasion  . RAP1 used PV marker (B). Scale
                                                                                   bars represent 5 â?®m. DIC, differential interference contrast.


                                                                                   tion complex, performed coimmunoprecipitation experi-
                                                                                   ments anti-RALP1 anti-AMA1 antibodies mature-
                                                                                   schizont-rich parasite extracts. Immunoprecipitation                                                                                    anti-RALP1-N1 anti-RALP1-C1 antibodies, pull                                                                                    RALP1 schizont lysates, brought length
                                                                                   RALP1 protein (approximately 90 kDa) processed RALP1
                                                                                   fragment (approximately 50 kDa) AMA1 RON4 (Fig.
                                                                                   3). reciprocal experiment, immunoprecipitated
                                                                                   AMA1 anti-AMA1 antibody, pulled AMA1
                                                                                   RON4 control RON-AMA1 complex                                                                                    RALP1. negative control, proteins detected                                                                                    immunoprecipitation experiment anti-GST antibody
                                                                                   (Fig. 3).
                                                                                       RALP1 binds human erythrocytes C-terminal
                                                                                   region. RALP1 protein possesses coiled-coil 
                                                                                   mains, including leucine zipper-like domain repre-
                                                                                   sent protein-protein interaction domain (Fig. 1A), local-
FIG 1 Structure, expression, localization RALP1 P. falciparum mero-
zoites.   Schematic primary structure RALP1. RALP1 protein         ized moving junction (Fig. 2), investigated RALP1
consists 749 aa calculated molecular mass 87.9 kDa. predicted     binds human erythrocytes. preferable use native
signal peptide (SP; residues 1 17), leucine zipper-like domain (LZ; residues    parasite RALP1 protein, Haase et al. (11) previously reported
511 532), coiled-coil domain (CC; residues 86 158 595 624)    RALP1 detectable parasite culture supernatants
indicated. RALP1-N1 (residues 35 148), RALP1-N2 (residues 17 412),
RALP1-C1 (residues 396 634), RALP1-C2 (residues 396 710)                                                                                    RALP1 appears partition insoluble fraction expressed recombinant proteins, antibodies raised RALP1-       late-stage parasite lysate  50 ), does N1, RALP1-C1, RALP1-C2. (B) SDS-PAGE recombinant RALP1 pro-                 contain predicted transmembrane domain GPI anchor signal.
teins. recombinant RALP1 proteins synthesized wheat        used recombinant GST-tagged RALP1 proteins germ cell-free protein expression purified affinity purification
columns. fractions purified RALP1-N1 (predicted molecular mass, 13.9
kDa), RALP1-C1 (27.5 kDa), RALP1-N2 (fused GST, 76.0 kDa), RALP1-C2 (37.4 kDa) proteins resolved 12.5  SDS-PAGE stained           probed rabbit anti-RALP1-C2 (green) mouse anti-RAP1 (rhop-
Coomassie brilliant blue R-250 shown. Arrowheads indicate bands        try bulb marker) antibodies   anti-RON4 (rhoptry neck marker) (mid-
length proteins. Asterisks represent bands truncated N2 proteins. (C)        dle) anti-RALP1-N1   (red) antibody. Parasite nuclei stained
tection RALP1 schizont lysate. Total schizont material examined       DAPI (blue). Scale bars represent 5 â?®m. DIC, differential interference
Western blotting reducing condition rabbit anti-RALP1-N1 (â?£-            contrast. (E) RALP1 localization shown IEM. sections merozoites N1), anti-RALP1-C1 (â?£-C1), anti-RALP1-C2 (â?£-C2) antisera. arrow-           schizont-infected erythrocytes probed purified rabbit anti-RALP1-C2
head indicates length RALP1, asterisks indicate processed N-      antibody subsequently secondary antibody conjugated gold C-terminal forms RALP1 protein. (D) RALP1 localization shown         particles shown. black dots indicate signals gold particles local- immunofluorescence assay. Paraformaldehyde-fixed mature schizonts               ized rhoptry necks. R, rhoptry.



4294     iai.asm.org                                                                                                                       Infection Immunity
                                                                                                        P. falciparum RALP1, Potential Malaria Vaccine Candidate




                                                                                  FIG 5 Anti-RALP1-C1 antibody invasion-inhibitory activity vitro.                                                                                   ability anti-RALP1-N1 (â?£-N1) anti-RALP1-C1 (â?£-C1) antibodies
                                                                                  inhibit parasite invasion erythrocytes tested cycle GIA.
                                                                                  Anti-AMA1 (â?£AMA1) anti-GST (â?£GST) antibodies used positive
                                                                                  negative controls, respectively. error bars represent standard er-
                                                                                  rors means independent experiments. Kruskal-Wallis test
                                                                                  performed, followed Dunnâ€™s multiple-comparison test, compare
                                                                                  percent inhibition anti-GST anti-RALP1-N1 antibodies anti-GST
                                                                                  anti-RALP1-C1 antibodies. ns, significant.
FIG 3 RALP1 does interact RON-AMA1 complex. Triton X-100
extracts schizont-rich parasite (PfTx extract) immunoprecipitated (IP) rabbit serum RALP1-N1, RALP1-C1, AMA1, GST detected Western blotting (WB) mouse antiserum RALP1-N1,          unknown. Considering erythrocyte-
RALP1-C1, AMA1, RON4. Immunoprecipitation anti-GST antibody               binding epitope middle region RALP1, designed used negative control. bands detected anti-GST im-        RALP1-N2, overlaps N terminus RALP1-C1 17 aa
munoprecipitate.                                                                  residues  e., N396 Q412). erythrocyte-binding activity                                                                                   RALP1-C1 (mean â«¾ standard error mean [SEM], EBA. EBA performed glutathione affinity-puri-                    4.6  â«¾ 0.7 ) significantly higher negative
fied, GST-tagged Rh5, RALP1-N2, RALP1-C1, GST (Fig. 4A).                      control, GST (2.3  â«¾ 0.4 ) (P â¬? 0.05). binding activity shown Fig. 1C, RALP1 undergoes processing cleavage                    RALP1-N2 similar GST (Fig. 4B). results middle portion;  precise cleavage site RALP1                suggest RALP1 erythrocyte-binding epitope C-
                                                                                  terminal region RALP1 new erythrocyte-binding pro-
                                                                                  tein P. falciparum.
                                                                                      Antibodies RALP1-C1 inhibit merozoite invasion. 
                                                                                  der test antibodies RALP1 block parasite 
                                                                                  vasion, rabbit polyclonal IgGs RALP1-N1 -C1 tested
                                                                                  inhibition parasite growth cycle replication                                                                                   measurement parasite growth flow cytometry. anti-
                                                                                  RALP1-N1, anti-RALP1-C1, anti-AMA1 (positive control),                                                                                   anti-GST (negative control) antibodies tested final 
                                                                                  centration 20 mg/ml (total IgG concentration), inhibited
                                                                                  invasion (mean â«¾ SEM) 10  â«¾ 0.8 , 39  â«¾ 1.6 , 51  â«¾
                                                                                  0.9 , 7.8  â«¾ 1.6 , respectively (Fig. 5). invasion-inhib-
                                                                                  iting activity anti-RALP1-C1 antibody significantly higher
                                                                                  negative-control anti-GST antibody (P â¬? 0.001).
                                                                                  Anti-RALP1-N1 antibody did significant inhibition ac-
                                                                                  tivity, inhibition activity negligible FIG 4 EBA recombinant RALP1.   SDS-PAGE recombinant pro-                anti-GST antibody.
teins used EBA. recombinant proteins synthesized         Anti-RALP1 antibodies cause merozoites aberrantly 
wheat germ cell-free protein expression GST fusion proteins         lease RAP1 IFA-based MIBA. understand purified affinity purification columns. fractions purified, GST-
tagged Rh5 (87 kDa), GST (27 kDa), RALP1-N2 (76 kDa), RALP1-C1 (55            mechanism invasion inhibition anti-RALP1-C1 anti-
kDa) proteins resolved SDS-PAGE stained Coomassie brilliant           body GIA, performed MIBA evaluates, IFA
blue R-250 shown. (B) Erythrocyte-binding activities recombinant           inspection, efficiency isolated viable, invasion-
RALP1 proteins. GST-tagged recombinant proteins incubated           competent merozoites invade erythrocytes presence 
human erythrocytes. recombinant proteins bound erythrocytes
                                                                                  tibodies. order count parasites invading erythrocytes stained FITC-conjugated anti-GST antibody. labeled erythro-
cytes counted flow cytometry. control, erythrocytes absence   distinguish pre- postinvasion merozoites, IFA recombinant proteins counted flow cytometry  .       performed DAPI labeling nuclear marker RAP1
vertical axis represents mean percentage erythrocytes bound        labeling PV marker. Figure 6A shows different states combinant protein calculated independent experiments. error         RAP1 release merozoite invasion erythrocytes: state 1,
bars indicate standard errors means independent experi-
ments. Kruskal-Wallis test performed, followed Dunnâ€™s multiple-        RAP1 unreleased  e., released); state 2, RAP1 properly
comparison test, compare means GST RALP1-N2 groups           released PV; state 3, RAP1 aberrantly released GST anti-RALP1-C1 groups. ns, significant.                            erythrocyte merozoite surface. untreated control, 


November 2013 Volume 81 Number 11                                                                                                               iai.asm.org 4295
Ito et al.




FIG 6 Anti-RALP1 antibody causes merozoites aberrantly release RAP1 MIBA.   Imaging erythrocyte-associated merozoites stained anti-
RAP1 antibody DAPI analysis RAP1 localization invasion presence anti-RALP1-C1 antibody. Merozoites categorized types based RAP1 staining patterns: 1, RAP1 unreleased; 2, RAP1
properly released PV; 3, RAP1 aberrantly released erythrocyte merozoite surface. scale bars represent 5 â?®m. DIC, differential inter-
ference contrast. (B) Stacked bar graph comparing mean percentages         FIG 7 Human sera areas Thailand Mali malaria endemic
merozoites types 1 3 (shown panel  presence anti-GST         recognize RALP1 ELISA. Probing RALP1-C1 sera P. falci-
(â?£GST) anti-RALP1-C1 (â?£-C1) antibody.                                          parum-infected asymptomatic Thai adults (Asymptomatic) naive, nonex-
                                                                                  posed Thai adults (Normal)   sera semi-immune adults                                                                                   Mali (Immune) naive, nonexposed U.S. adults (Normal) (B). P values
formed MIBA incomplete culture medium                          calculated Mann-Whitney U test. number (n) serum samples
                                                                                  analyzed shown. (C) Correlation anti-RAPL1-C1 antibody titers
antibodies. significant difference observed                  (logarithmic scale) vitro growth-inhibitory activities Mali semi- total number merozoites associated untreated eryth-                   immune serum samples. graph shows significant positive correlation
rocytes associated erythrocytes treated                 antibody titers growth-inhibitory activities (Spearmanâ€™s rank
anti-GST antibody (mean â«¾ SEM, 108  â«¾ 5  untreated-                        correlation, r â«½ 0.51; 95  confidence interval, 0.14 0.75; P â¬? 0.01). OD,
                                                                                  optical density; dil., dilution.
control value) anti-RALP1-C1 antibody (112  â«¾ 5 ). Fur-
thermore, proportion parasites unreleased RAP1 (Fig.
6A, state 1) observed presence anti-RALP1-C1 (â?£-C1)                     Sera asymptomatic Thai adults (asymptomatic) showed signif-
antibody significantly different (Fisherâ€™s exact test ad-                 icantly higher reactivity RALP1-C1 malaria-naive
justed P â«½ 0.48) observed presence anti-GST                      Thai individuals (normal) (P â¬? 0.01, Mann-Whitney U test) (Fig.
(â?£GST) antibody (Fig. 6B, state 1).                                               7A), sera semi-immune adults Mali (Immune)
     proportion merozoites invaded (Fig.                  showed significantly higher reactivity RALP1-C1 6A, state 2) (measured counting properly secreted RAP1 stain-                  malaria-naive U.S. adults (normal) (P â¬? 0.01, Mann-Whitney U
ing) significantly reduced anti-RALP1-C1 antibody com-                     test) (Fig. 7B). evaluated functional activity purified
pared anti-GST antibody (Fisherâ€™s exact test adjusted P â¬?                      IgGs Malian sera P. falciparum 3D7 parasites 0.001) (Fig. 6B, state 2). Importantly, proportion merozo-                 vitro GIA investigate correlation antibody titer
ites released RAP1 aberrantly (Fig. 6A, state 3) signifi-                RAPL1-C1 vitro growth-inhibitory activity. cantly higher presence anti-RALP1-C1 antibody                   shown Fig. 7C, significant positive correlation  presence control anti-GST antibody (Fisherâ€™s exact test ad-                tween antibody titer growth-inhibitory activity (Spearmanâ€™s
justed P â¬? 0.001) (Fig. 6B, state 3). Samples tested tripli-              rank correlation, r â«½ 0.51; 95  confidence interval, 0.14 0.75;
cate experiment. independent experiments                         P â¬? 0.01). Taken  results suggest RALP1 performed  Fig. S2 supplemental material),                    immunogenic malaria infection humans. results agreement Fig. 6B. short, results suggest anti-RALP1 antibody affects merozoite inva-                  DISCUSSION
sion erythrocytes merozoite attachment erythro-                     RALP1 P. falciparum previously specifically
cytes.                                                                            expressed schizont stages localized rhoptry mero-
    Reactivity RALP1 human immune sera. anti-                         zoites basis IFA. refractory gene
RALP1 antibodies inhibited merozoite invasion vitro (Fig. 5                knockout attempts, suggesting RALP1 essential blood-
6B), decided investigate RALP1 exposed                    stage parasite survival;  RAPL1 experimen-
human immune P. falciparum-infected individuals                     tally characterized vaccine candidate.  aimed char-
generates immune response. order test presence                acterize RALP1 P. falciparum blood-stage vaccine candidate
anti-RALP1 antibody sera, tested sera P. falci-                    using recombinant RALP1 expressed wheat germ cell-
parum-infected asymptomatic adults western Thailand na-                    free 
ive, nonexposed Thai adults antibodies RALP1-C1 recom-                         Western blotting results (Fig. 1C) agreement binant protein ELISA (Fig. 7A) sera semi-immune                       previous report (11) primary processing events occur adults Mali, western Africa, naive, nonexposed U.S.                   RALP1. addition, IEM results (Fig. 1E) confirmed adults antibodies RALP1-C1 recombinant protein (Fig. 7B).                  time RALP1 localized merozoite


4296     iai.asm.org                                                                                                                      Infection Immunity
                                                                                                P. falciparum RALP1, Potential Malaria Vaccine Candidate



rhoptry neck,  RALP1 represents novel RON. Fur-               reside outside leucine zipper-like domain (residues 511 532
thermore, IFA results obtained merozoites invading               Fig. 1A) coiled-coil domain (residues 595 624 Fig. 1A)
erythrocytes (Fig. 2) revealed RALP1 translocates mov-        RALP1. preliminary SNP analyses suggest leu-
ing junction invasion RALP1 novel tight-            cine zipper-like domain coiled-coil domain RAPL1 junction protein. RALP1 tight-junction protein, ex-         essential function protein.  validate pected RALP1 component RON-AMA1                    claim, need analysis SNPs RALP1 different field
complex.  immunoprecipitation results showed             isolates worldwide. AMA1 RON4 immunoprecipitated                        Overall, findings indicate RALP1 novel rhoptry
RALP1, suggesting RALP1 RON-AMA1                  neck erythrocyte-binding blood-stage antigen P. falciparum
complex (Fig. 3). fact RALP1 novel tight-junction           merozoites, immunogenic antigen humans protein (Fig. 2) erythrocyte-binding epitope C-ter-        target antibodies contribute acquired immu-
minal region (Fig. 4) suggests RALP1 plays role bridging      nity falciparum malaria.  RALP1 potential
protein erythrocyte surface merozoite sur-            blood-stage vaccine candidate antigen P. falciparum. study
face.  lack transmembrane region RALP1 (Fig.          substantiates claims wheat germ cell-free 1A) suggests RALP1 associated unknown               valuable tool identification novel malaria vaccine
membrane protein anchored merozoite surface               candidates.
RALP1 plays role invasion ligand, Rh proteins
(10, 27).  studies required RALP1       ACKNOWLEDGMENTS
receptor erythrocyte membrane possible merozoite               grateful adults Kenieroba, Mali, donated sera, surface proteins anchor RALP1 parasite surface.               appreciate efforts Rick Fairhurst, Mahamadou Diakite, Jennifer
    GIA MIBA measure capacity antibodies limit              Anderson, Saibou Doumbia facilitating availability sera.
parasite growth invasion P. falciparum vitro (28).       grateful Jean F. Dubremetz anti-RON4 monoclonal
GIA MIBA results anti-RALP1 antibodies specifi-             antibody. thank Masachika Shudo, Integrated Center Science,
cally inhibited invasion erythrocytes merozoites        Ehime University, Japan technical assistance. thank Japa- attachment merozoites erythrocytes. MIBA results            nese Red Cross Society providing human erythrocytes human
                                                                          plasma.
clearly anti-RALP1 antibody caused merozoites                                                                               work supported MEXT KAKENHI (23117008) aberrantly release RAP1 merozoite erythrocyte surface         JSPS KAKENHI (23406007) Japan grant Ministry host cell negative control did, suggesting      Health, Labor, Welfare (H21-Chikyukibo-ippan-005), Japan. RALP1 plays important role correct tight-junction          study Malian samples supported intramural program mation normal release RAP1 host cell.             NIAID, NIH, PATH Malaria Vaccine Initiative.
aberrant RAP1 release observed study akin previ-
ously described abortive merozoite invasion anomalous              REFERENCES
premature rhoptry bulb release merozoite invasion            1.  2011. World malaria report 2011. Press, Geneva, Switzer-
presence R1 inhibitory peptide blocks formation            land.
                                                                           2. Crompton PD, Pierce SK, Miller LH. 2010. Advances challenges RON-AMA1 complex (26). data consistent                                                                               malaria vaccine development. J. Clin. Invest. 120:4168 â€“ 4178.
previous finding (26) rhoptry bulb release correct tight-         3. Greenwood BM, Targett GA. 2011. Malaria vaccines new malaria
junction formation occur independently triggered                 agenda. Clin. Microbiol. Infect. 17:1600 â€“1607. committed merozoite attachment event likely initiated             4. Birkett AJ. 2010. PATH Malaria Vaccine Initiative (MVI): perspectives erythrocyte-binding-like/Rh proteins (26).                                 status malaria vaccine development. Hum. Vaccin. 6:139 â€“145.
                                                                           5. Cowman AF, Crabb BS. 2006. Invasion red blood cells malaria
    Immunoreactive antigens involved erythrocyte invasion                  parasites. Cell 124:755â€“766.
represent potential candidates malaria vaccine (29),            6. Iyer J, Gruner AC, Renia L, Snounou G, Preiser PR. 2007. Invasion signing vaccine based sequences immunoreactive antigens               host cells malaria parasites: tale protein families. Mol. Micro- minimum polymorphisms critical preventing para-                biol. 65:231â€“249.
                                                                           7. Preiser P, Kaviratne M, Khan S, Bannister L, Jarra W. 2000. apical
site evading vaccine-induced immunity.                                                                               organelles malaria merozoites: host cell selection, invasion, host immu-
GIA results (Fig. 5) indicate antibodies RALP1-C1                nity immune evasion. Microbes Infect. 2:1461â€“1477. invasion-inhibitory activity, immunoscreening              8. Alexander DL, Arastu-Kapur S, Dubremetz JF, Boothroyd JC. 2006.
sults (Fig. 7) demonstrate significant correlation       Plasmodium falciparum AMA1 binds rhoptry neck protein homologous reactivity Mali semi-immune sera                   TgRON4, component moving junction Toxoplasma gondii.
                                                                              Eukaryot. Cell 5:1169 â€“1173.
RAPL1-C1 vitro growth-inhibitory activity, suggesting          9. Cao J, Kaneko O, Thongkukiatkul  Tachibana M, Otsuki H, Gao Q,
RALP1-C1 contains invasion-inhibitory epitope corre-                  Tsuboi T, Torii M. 2009. Rhoptry neck protein RON2 forms complex
lates immunity humans developed following natural                  microneme protein AMA1 Plasmodium falciparum merozoites.
fection areas malaria endemic.                                    Parasitol. Int. 58:29 â€“35.
                                                                          10. Gunalan K, Gao X, Yap SS, Huang X, Preiser PR. 2013. role     Previous preliminary single nucleotide polymorphism (SNP)
                                                                     